Advertisement

Topics

BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer

09:16 EST 21 Nov 2018 | FinanzNachrichten

Further senior organisational changes made in preparation for advancing bemcentinib into the next stage of clinical development in multiple aggressive cancers BERGEN, Norway, Nov. 21, 2018 /PRNews...

Original Article: BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer

NEXT ARTICLE

More From BioPortfolio on "BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer"

Advertisement
Quick Search
Advertisement
Advertisement